Gonapeptyl

Gonapeptyl is a prescription medication that contains the active ingredient triptorelin acetate, a synthetic gonadotropin‑releasing hormone (GnRH) agonist. It is supplied for subcutaneous injection; specific strength and dosage form are not disclosed in this summary. The product is marketed in the European Union under ATC code L02AE02 for reproductive hormone therapy and works by down‑regulating pituitary GnRH receptors, reducing LH and FSH secretion in the body.

Gonapeptyl is indicated for several hormone‑dependent conditions where suppression of gonadal steroid production is required.

- Management of advanced or metastatic prostate cancer by reducing testosterone levels. - Treatment of endometriosis to induce a hypo‑estrogenic state and relieve pelvic pain. - Reduction of uterine fibroid size and associated bleeding through hormonal suppression. - Control of central precocious puberty by halting premature activation of the hypothalamic‑pituitary‑gonadal axis. - Adjunct in assisted reproductive technology to prevent premature luteinizing hormone surge during controlled ovarian stimulation. - Used in combination with other hormonal agents for specific gynecologic protocols requiring temporary estrogen suppression.

The safety profile of Gonapeptyl reflects the pharmacologic action of GnRH agonists; side effects are related to reduced sex hormone levels and the initial stimulation phase.

Common: - Hot flashes, sweating, or night sweats. - Decreased libido or erectile dysfunction in men; reduced sexual desire in women. - Headache or mild dizziness. - Injection site reactions such as redness, swelling, or pain.

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty. - Cardiovascular events including hypertension, arrhythmia, or myocardial infarction. - Bone mineral density loss leading to osteoporosis with long‑term use.

Before initiating Gonapeptyl, clinicians should evaluate patient history and consider specific warnings to minimize risks.

- Assess cardiovascular status; use cautiously in patients with hypertension, coronary artery disease, or recent myocardial infarction. - Evaluate bone health; prolonged therapy may increase risk of osteoporosis or fractures. - Screen for hormone‑dependent tumors; avoid use in active breast or ovarian cancer. - Monitor liver function; rare cases of hepatic dysfunction have been reported. - Consider potential flare effect; initial GnRH agonist stimulation can transiently increase hormone levels. - Use only under specialist supervision during pregnancy planning, as fetal exposure effects are unknown.

Gonapeptyl can alter the metabolism or effectiveness of several concomitant medications; awareness of interactions helps maintain therapeutic outcomes.

Avoid: - Concomitant use with other GnRH agonists or antagonists, which may cause excessive hormone suppression. - Strong estrogen‑containing hormonal therapies, as they counteract the intended hypo‑estrogenic effect.

Use with caution: - Anticoagulants, because injection site bleeding may be prolonged. - Antidiabetic agents, since hormonal changes can affect glucose control. - Corticosteroids, which may exacerbate bone loss during prolonged GnRH agonist therapy. - Thyroid hormone replacement, as GnRH agonists can influence thyroid‑binding globulin levels.